Amylyx Pharmaceuticals, Inc.
AMLX
$14.48
$0.271.87%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -27.05% | 23.05% | |||
| Gross Profit | 27.05% | -23.05% | |||
| SG&A Expenses | 3.40% | -0.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.94% | 13.37% | |||
| Operating Income | 15.94% | -13.37% | |||
| Income Before Tax | 17.03% | -15.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.03% | -15.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.03% | -15.42% | |||
| EBIT | 15.94% | -13.37% | |||
| EBITDA | 15.94% | -13.46% | |||
| EPS Basic | 20.76% | -10.95% | |||
| Normalized Basic EPS | 20.75% | -10.96% | |||
| EPS Diluted | 20.76% | -10.95% | |||
| Normalized Diluted EPS | 20.75% | -10.96% | |||
| Average Basic Shares Outstanding | 4.71% | 4.02% | |||
| Average Diluted Shares Outstanding | 4.71% | 4.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||